India · Delayed Price · Currency is INR Windlas Biotech Statistics
Total Valuation
Windlas Biotech has a market cap or net worth of INR 16.49 billion. The enterprise value is 14.19 billion.
| Market Cap | 16.49B |
| Enterprise Value | 14.19B |
Important Dates
The last earnings date was Thursday, November 6, 2025.
| Earnings Date | Nov 6, 2025 |
| Ex-Dividend Date | Jul 21, 2025 |
Share Statistics
Windlas Biotech has 20.96 million shares outstanding. The number of shares has increased by 1.08% in one year.
| Current Share Class | 20.96M |
| Shares Outstanding | 20.96M |
| Shares Change (YoY) | +1.08% |
| Shares Change (QoQ) | +0.05% |
| Owned by Insiders (%) | 62.40% |
| Owned by Institutions (%) | 9.83% |
| Float | 7.60M |
Valuation Ratios
The trailing PE ratio is 24.79.
| PE Ratio | 24.79 |
| Forward PE | n/a |
| PS Ratio | 1.99 |
| PB Ratio | 3.09 |
| P/TBV Ratio | 3.13 |
| P/FCF Ratio | 37.48 |
| P/OCF Ratio | 17.46 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 13.58, with an EV/FCF ratio of 32.26.
| EV / Earnings | 21.09 |
| EV / Sales | 1.71 |
| EV / EBITDA | 13.58 |
| EV / EBIT | 18.85 |
| EV / FCF | 32.26 |
Financial Position
The company has a current ratio of 2.06, with a Debt / Equity ratio of 0.06.
| Current Ratio | 2.06 |
| Quick Ratio | 1.68 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | 0.30 |
| Debt / FCF | 0.71 |
| Interest Coverage | 15.49 |
Financial Efficiency
Return on equity (ROE) is 13.39% and return on invested capital (ROIC) is 19.08%.
| Return on Equity (ROE) | 13.39% |
| Return on Assets (ROA) | 6.03% |
| Return on Invested Capital (ROIC) | 19.08% |
| Return on Capital Employed (ROCE) | 13.92% |
| Weighted Average Cost of Capital (WACC) | 5.69% |
| Revenue Per Employee | 6.17M |
| Profits Per Employee | 500,156 |
| Employee Count | 1,346 |
| Asset Turnover | 1.06 |
| Inventory Turnover | 6.77 |
Taxes
In the past 12 months, Windlas Biotech has paid 206.85 million in taxes.
| Income Tax | 206.85M |
| Effective Tax Rate | 23.50% |
Stock Price Statistics
The stock price has decreased by -19.60% in the last 52 weeks. The beta is 0.24, so Windlas Biotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.24 |
| 52-Week Price Change | -19.60% |
| 50-Day Moving Average | 790.15 |
| 200-Day Moving Average | 911.22 |
| Relative Strength Index (RSI) | 51.82 |
| Average Volume (20 Days) | 41,542 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Windlas Biotech had revenue of INR 8.30 billion and earned 673.21 million in profits. Earnings per share was 31.73.
| Revenue | 8.30B |
| Gross Profit | 3.15B |
| Operating Income | 753.11M |
| Pretax Income | 880.06M |
| Net Income | 673.21M |
| EBITDA | 1.02B |
| EBIT | 753.11M |
| Earnings Per Share (EPS) | 31.73 |
Balance Sheet
The company has 2.61 billion in cash and 312.09 million in debt, with a net cash position of 2.29 billion or 109.44 per share.
| Cash & Cash Equivalents | 2.61B |
| Total Debt | 312.09M |
| Net Cash | 2.29B |
| Net Cash Per Share | 109.44 |
| Equity (Book Value) | 5.34B |
| Book Value Per Share | 254.44 |
| Working Capital | 2.90B |
Cash Flow
In the last 12 months, operating cash flow was 944.52 million and capital expenditures -504.55 million, giving a free cash flow of 439.97 million.
| Operating Cash Flow | 944.52M |
| Capital Expenditures | -504.55M |
| Free Cash Flow | 439.97M |
| FCF Per Share | 20.99 |
Margins
Gross margin is 37.89%, with operating and profit margins of 9.07% and 8.11%.
| Gross Margin | 37.89% |
| Operating Margin | 9.07% |
| Pretax Margin | 10.60% |
| Profit Margin | 8.11% |
| EBITDA Margin | 12.30% |
| EBIT Margin | 9.07% |
| FCF Margin | 5.30% |
Dividends & Yields
This stock pays an annual dividend of 5.80, which amounts to a dividend yield of 0.72%.
| Dividend Per Share | 5.80 |
| Dividend Yield | 0.72% |
| Dividend Growth (YoY) | 5.45% |
| Years of Dividend Growth | 4 |
| Payout Ratio | 35.13% |
| Buyback Yield | -1.08% |
| Shareholder Yield | -0.35% |
| Earnings Yield | 4.08% |
| FCF Yield | 2.67% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 7 |